OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain - OSIREAL

Study identifier:D5162R00034

ClinicalTrials.gov identifier:NCT06068049

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

An ambispective, non-interventional, multiple cohort study to assess the management of osimertinib treatment in patients with EGFRm non-small cell lung cancer under real-world conditions in Spain

Medical condition

Non-small Cell Lung Cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

300

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 28 Jul 2023
Estimated Primary Completion Date: 15 Jun 2029
Estimated Study Completion Date: 15 Jun 2029

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria